Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 100,117 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $29.38, for a total transaction of $2,941,437.46. Following the completion of the transaction, the insider owned 157,217 shares of the company’s stock, valued at approximately $4,619,035.46. This represents a 38.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):
- On Tuesday, November 3rd, Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.89, for a total transaction of $3,327,145.57.
- On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.84, for a total transaction of $1,310,871.20.
- On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28.
- On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total transaction of $3,304,428.49.
- On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total transaction of $2,664,822.66.
- On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
- On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
- On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
- On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
- On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total value of $3,960,491.56.
Alamar Biosciences Stock Down 3.0%
ALMR traded down $0.95 during trading on Friday, hitting $30.81. The company’s stock had a trading volume of 667,712 shares, compared to its average volume of 745,923. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61. The business’s fifty day simple moving average is $30.25 and its 200 day simple moving average is $27.16.
Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The business had revenue of $33.55 million during the quarter. Alamar Biosciences had a negative return on equity of 78.71% and a negative net margin of 48.22%. Analysts predict that Alamar Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alamar Biosciences
Large investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alamar Biosciences during the third quarter valued at approximately $196,000. Squarepoint Ops LLC acquired a new stake in shares of Alamar Biosciences in the second quarter worth approximately $283,000. Palumbo Wealth Management LLC boosted its stake in shares of Alamar Biosciences by 16.5% in the third quarter. Palumbo Wealth Management LLC now owns 16,934 shares of the company’s stock worth $577,000 after acquiring an additional 2,402 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Alamar Biosciences in the third quarter worth approximately $606,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after purchasing an additional 10,461 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on ALMR. TD Cowen boosted their price target on shares of Alamar Biosciences from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Weiss Ratings raised shares of Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, November 4th. Stifel Nicolaus increased their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.
View Our Latest Analysis on Alamar Biosciences
Alamar Biosciences Company Profile
Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine. The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation.
Featured Articles
- Five stocks we like better than Alamar Biosciences
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
